NasdaqCM - Nasdaq Real Time Price USD

Atossa Therapeutics, Inc. (ATOS)

2.1700 -0.0600 (-2.69%)
At close: October 30 at 4:00:01 PM EDT
2.2793 +0.1093 (+5.04%)
After hours: October 30 at 5:25:49 PM EDT
Chart Range Bar
Loading chart for ATOS
  • Previous Close 2.2300
  • Open 2.2500
  • Bid 2.2200 x 200
  • Ask 2.2600 x 300
  • Day's Range 2.1500 - 2.4300
  • 52 Week Range 1.7000 - 14.8500
  • Volume 32,231
  • Avg. Volume 70,853
  • Market Cap (intraday) 21.655M
  • Beta (5Y Monthly) 1.27
  • PE Ratio (TTM) --
  • EPS (TTM) -4.4500
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 19.00

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

www.atossatherapeutics.com

16

Full Time Employees

December 31

Fiscal Year Ends

Recent News

View More
Atossa plans shareholder stake in potential PRV proceeds

Atossa plans shareholder stake in potential PRV proceeds

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ATOS
75.48%
S&P 500 (^GSPC)
10.73%

1-Year Return

ATOS
83.56%
S&P 500 (^GSPC)
11.11%

3-Year Return

ATOS
77.74%
S&P 500 (^GSPC)
81.91%

5-Year Return

ATOS
94.37%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -8.49M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
-8M
-6M
-4M
-2M
0
0.0%
 

Analyst Insights

View More

Analyst Price Targets

10.00
19.00 Average
2.1700 Current
25.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/1/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 24 -> 25
 

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    21.75M

  • Enterprise Value

    -4.34M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.81

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -50.69%

  • Return on Equity (ttm)

    -89.23%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -37.71M

  • Diluted EPS (ttm)

    -4.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.09M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -23.33M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.1700 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch